Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare

Continuation Of 2022 Initiatives

Jan 09 2023

• By Jung Won Shin

Keywords — Home-grown New Drug Approvals Drop In Korea Last Year • Source: Shutterstock

Related Content

Lunsumio Provides First Test For Korea's Breakthrough Therapy Program

Dec 02 2022

Korea’s Home-Grown New Drug Approvals Hit Record High In 2021

Apr 12 2022

Daewoong's SGLT-2 Inhibitor Set For First Filing After Phase III

Feb 07 2022

Third Time Lucky As Japan Finally Approves Shionogi’s Oral COVID Antiviral

Nov 24 2022

Korea Readying Itself For New Era Of Digital Therapeutics

Nov 23 2022

SK Bioscience First To Line In Korea COVID Vaccine Race

Jun 30 2022

Korea’s Regulatory Innovation Steps Focus On Investment, New Technologies

Jul 29 2022

Related Companies

Roche Holding AG

Daewoong Pharmaceutical Company Ltd.

SK Bioscience

Takeda Pharmaceutical Co. Ltd.

GSK plc

Bristol Myers Squibb Company

Janssen Pharmaceutical Cos.

Ildong Pharmaceutical Co., Ltd.

Shionogi & Co. Ltd.

Yuhan Corporation

Celltrion, Inc.

Hanmi Pharmaceutical Co., Ltd.

Gilead Sciences, Inc.

Additional Topics

South Korea Asia Pacific Regulation Pink Sheet Perspectives BioPharmaceutical

More from South Korea

More from Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window